Supporting this is the observation that non-leukemic clones harboring mutations in TP53, DNMT3A, PPM1D, SRCAP and ZNF318 may rapidly expand with treatment of the AML/MDS clone40–42. This evidence concerns the gene ZNF318 and myelodysplastic syndrome.